CAS 552-02-3 Viridiflorol - Analytical Products / Alfa Chemistry

CAT	AP552023
CAS	552-02-3
Structure
MDL Number	MFCD28899097
Molecular Weight	222.37
EC Number	209-003-3
InChI Key	AYXPYQRXGNDJFU-IMNVLQEYSA-N

Description	analytical standard
Assay	≥95.0% (GC)
Grade	analytical standard
Size	10MG

Anti-inflammatory, Antioxidant and anti-Mycobacterium Tuberculosis Activity of Viridiflorol: The Major Constituent of Allophylus Edulis (A. St.-Hil., A. Juss. & Cambess.) Radlk

Lucas Noboru Fatori Trevizan, Kamilla Felipe do Nascimento, Joyce Alencar Santos, Candida Aparecida Leite Kassuya, Claudia Andrea Lima Cardoso, Maria do Carmo Vieira, Flora Martinez Figueira Moreira, Julio Croda, etc.

J Ethnopharmacol. 2016 Nov 4;192:510-515.

PMID: 27612433

Antimicrobial Activity of Five Essential Oils From Lamiaceae Against Multidrug-Resistant

Barbara Kot, Kamila Wierzchowska, Małgorzata Piechota, Paweł Czerniewicz, Grzegorz Chrzanowski

Nat Prod Res. 2019 Dec;33(24):3587-3591.

PMID: 29888957

Is a 1,4-Alkyl Shift Involved in the Biosynthesis of Ledol and Viridiflorol?

Young J Hong, Dean J Tantillo

J Org Chem. 2017 Apr 7;82(7):3957-3959.

PMID: 28277661

Structure and Cytotoxic Activity of Sesquiterpene Glycoside Esters From Calendula Officinalis L.: Studies on the Conformation of Viridiflorol

Michele D'Ambrosio, Alexandru Ciocarlan, Elisa Colombo, Antonio Guerriero, Cosimo Pizza, Enrico Sangiovanni, Mario Dell'Agli

Phytochemistry. 2015 Sep;117:1-9.

PMID: 26057223

Systematic Engineering for High-Yield Production of Viridiflorol and Amorphadiene in Auxotrophic Escherichia Coli

Sudha Shukal, Xixian Chen, Congqiang Zhang

Metab Eng. 2019 Sep;55:170-178.

PMID: 31326469

* Products or Services Interested: Viridiflorol (552-02-3)
* Your question
* Name
* Email
Verification Code

Case Study

Potential Anti-Arthritis and Analgesic Properties of Essential Oils and Viridiflorol in Mice

de Matos Balsalobre, Natália, et al. Journal of Ethnopharmacology 301 (2023): 115785.

The aim of this study was to investigate the analgesic (anti-hyperalgesic and anti-nociceptive) and anti-arthritis properties of EOAE and viridiflorol using in vivo models.
Oral administration of EOAE (100 and 300 mg/kg) and viridiflorol (200 mg/kg), subcutaneous morphine (1 mg/kg), and local application of viridiflorol (100 μg/paw) significantly inhibited edema and nociception in the formalin model. Oral administration of EOAE and viridiflorol (200 mg/kg) did not cause motor impairment in the open field test, as they did not reduce locomotor activity. EOAE, viridiflorol, and dexamethasone significantly reduced mechanical hyperalgesia, edema, total leukocytes, polymorphonuclear cells, nitric oxide, and protein exudation in the yeast glucan-induced arthritis model. Local administration of viridiflorol (200 μg/paw, i.pl.) significantly inhibited mechanical hyperalgesia and edema induced by carrageenan, TNF-α, and DOPA. This study confirms the potential anti-arthritis, anti-nociceptive, and anti-hyperalgesic properties of EOAE and viridiflorol. These properties may at least partially explain the traditional use of A. edulis for pain relief. viridiflorol may contribute to the anti-hyperalgesic, anti-nociceptive, and anti-arthritis properties of EOAE, with mechanisms possibly involving the inhibition of the TNF-α and DOPA pathways.

Viridiflorol Induces Anti-Neoplastic Effects on Breast, Lung, and Brain Cancer Cells

Akiel, Maaged A., et al. Saudi Journal of Biological Sciences 29.2 (2022): 816-821.

Despite the potential of many natural molecules as therapeutic agents, they remain underutilized, hindering the progress of anticancer drug discovery. Viridiflorol, a natural volatile compound, shows promise as an anti-cancer agent.
We evaluated the anticancer properties of viridiflorol at concentrations ranging from 0.03 to 300 μM in vitro against three cancer cell lines: breast (MCF-7), lung (A549), and brain (Daoy). The responses of the cancer cells to treatment were assessed using MTT and Annexin V assays. Our results demonstrated that viridiflorol exhibited cytotoxic effects across all tested cell lines, reducing cell viability in a concentration-dependent manner with varying IC50 values. Notably, the Daoy and A549 cell lines were more sensitive to viridiflorol than to temozolomide and doxorubicin, respectively. Viridiflorol displayed the highest anticancer activity against Daoy cells, with an estimated IC50 of 0.1 µM, followed by MCF-7 at 10 µM and A549 at 30 µM. Furthermore, exposure to viridiflorol at concentrations between 30 µM and 300 µM induced early and late apoptotic cell death in a concentration-dependent manner, with Daoy (55.8%-72.1%), MCF-7 (36.2%-72.7%), and A549 (35%-98.9%) cell lines showing varying rates of apoptosis.
In conclusion, viridiflorol demonstrates significant cytotoxic and apoptotic abilities in three different cancer cell lines: brain, breast, and lung.